Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lung Cancer Metastatic 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1Coronary Disease 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Atherosclerosis 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × evolocumab × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05976893 2023-08-04

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Xinjiang Medical University

Phase 4 Unknown
620 enrolled

Neoplasms, Atherosclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡